Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Aging and retinal vascular diseases].

Hitoshi Takagi¹

¹Department of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, Japan.

Nippon Ganka Gakkai Zasshi

|April 4, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

Clinical Utility of the aMAP Risk Score for Predicting the Recurrence of Hepatic Encephalopathy After Rifaximin Treatment in Patients With Liver Cirrhosis: A Retrospective Cohort Study.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

The Influence of Primary Femoral Bone Tunnel Position on Postoperative Outcomes and Femoral Bone Tunnel Creation in Revision ACL Reconstruction.

The journal of knee surgery·2025

Same author

Predictors of Disengagement and Loss to Follow-Up of Intravitreal Injection for Neovascular Age-Related Macular Degeneration in a Real-World Clinical Setting: Post Hoc Analysis of the Multicenter Survey from the Japanese Clinical Retinal Study (J-CREST) Group.

Journal of clinical medicine·2025

Same author

Cystoid macular oedema after flanged intraocular lens scleral fixation using the Yamane technique: a multicentre cohort study.

Scientific reports·2025

Same author

Changes in Aqueous Angiopoietin-1/2 Concentrations During the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema.

Translational vision science & technology·2024

Ocular vascular diseases stem from aging and lifestyle factors, leading to vision loss. Targeting stress kinases, Angiopoietin 1, and VEGF pathways offers novel therapeutic strategies for retinal vascular damage.

Area of Science:

Ocular vascular biology
Molecular mechanisms of vascular aging
Retinal disease pathology

Context:

Aging populations face increasing rates of ocular vascular diseases like diabetic retinopathy and age-related macular degeneration.
These conditions cause severe visual impairment due to macular edema, retinal detachment, and neovascular glaucoma.
Vascular cell aging and damage, exacerbated by lifestyle diseases (diabetes, hypertension, obesity), are key contributors.

Purpose:

Investigate molecular mechanisms underlying ocular vascular deficiencies.
Propose novel therapeutic strategies for age-related and lifestyle-induced vascular diseases in the eye.
Identify key molecular targets for retina-specific therapies.

Summary:

Stress kinases mediate vascular cell apoptosis induced by oxidative and mechanical stress; their inhibition may protect against age-related damage.

Related Experiment Videos

Pericyte-derived Angiopoietin 1 (Ang 1) plays a crucial role in maintaining retinal vasculature by suppressing stress signaling and normalizing pathology.

Neuropilin 1 (NRP 1) enhances VEGF receptor function and is a potential target for retina-specific therapies, while erythropoietin also acts as an angiogenic factor in proliferative diabetic retinopathy.

Impact:

Findings suggest stress kinase inhibitors as a treatment for age-related vascular damage.
Ang 1's paracrine action highlights its therapeutic potential for pericyte loss-related vascular pathologies.
Identifying NRP 1, renin-angiotensin system components, adipocytokines, and erythropoietin as therapeutic targets offers new avenues for treating complex ocular vascular diseases.